The aim of the treatment study was to interfere with the coagulative as well as the fibrinolytic properties of the tumours. To 18 women over 70 years off age, and not suitable for treatment with eytostatics, the anticoagulant Warfarin was given together with the f~brinolytie inhibitor tranexamic acid (Cyklokapron) in a dosage of 4 g daily. All patients were operated upon and six were maeroscopically radical (3 stage I, 2 stage If, I stage Ill). Twelve patients had advanced stage Ill and IV, with balky disease after surgery. Four of them had liver metastasis.
The five patients in stage I-If and radically operated are alive with a median survival time of 51+ months (range 21+ -58+). The median survival of the 13 patients in stage Ill-IV is eight months (range 2 -72+). Three of them, including two with liver metastasis, are alive and in a good clinical state. One of the latter has the most prolonged survival time of 72+ months.
A certain time seems necessary for this therapy to exert its effect. By starting treatment of advanced tumours with combined Warfarin/tranexamic acid and eytostaties, the often good initial effect of cytostatics should enable Warfarin/tranexamie acid to exert its prolonged effect. Ki-24 (STEIN et al., 1982) and in addition the Interleukin-2-receptor (STEIN et al., 1985; HSU et al., 1985 All had in common an infection with Epstein-Barr-Virus (EBV) and an immune deficiency of variable degree. Further virological and serological research led to the description of the so-called "X-linked Lymphoproliferative Syndrome" or "Duncan's Disease" after the firstly described family. As only male family members were affected, an Xchromosomal mode of inheritance was proposed.~The following immunopathogenetic mechanisms have been discussed: EB-Viruses infect B-lymphocytes, leading to a polyclonal proliferation of EBV-infected cells. Due to an immune defect, there is insufficient production of EBV-antibodies and killer-T-lymphocytes which eliminate EBV-infected Bcells. We present a family in which two sons have got !ymphogranu!omatosis. They died at the age of 12 and 20 years from stage IV B Hodgkin{s disease. The third son, 19 years old, was followed up for one year for suspected Hodgkin's disease, his moderately elevated EBV-titers being ascribed to this disease. Ad the same time he had a constant deficiency of immnnoglobulins. Upon clinical progression another biopsy led to the diagnosis of a polymorphic lymphoplasmacytoid immunocytoma. In this lymph node EBV DNA was demonstrated. Together with the family history this leads to the diagnosis of Duncan's Syndrome. There was no evidence of HLA-linkage of the lymphoproliferative disorder. Althoug there was no numerical aberration of T and B lymphocytes and the subpopulations a functional defect of cellular immunity (areactivity by MLC-testing) could be demonstrated. This can he taken as evidence of a functional T cell defect which favours the development of a lymphoproliferative disease. Non-endemic lymphoblastic NHL of Burkitt-tyDe is a rare disease in adults, aecountina for only 2% of all NHL. Prognosis in this ame qrouD is poor with a 2-year survival rate of 30%. Durinq recent years, 13 patients with Burkitt Ivmphoma were treated at this institution. The median age of the patients was 25(range 14-46) years. Chemotherapy consisted of cyclomhosphamide, vincristine, methotrexate and prednisone(COMP) in 5 patients. Mere recently, 4 patients were treated with a combination chemotherapy consisting of medium-dose methotrexate with leucovorinerescue, cyclophosnhamide, tenimoside, cytarabin, adriamvcin and prednisone and central nervous system prophylaxis with i.th. methotrexate and 24 Gy cranial irradiation. In the 4 evaluable patients treated with COMP there were 2 complete remissions{OR) who are in continious CR for 38+ and 81+ months respectively. Progressive disease occurred in the remaining 2 patients,who died after 4 and 6 months, respectively. By contrast all patients recei~ ving the recently emnloyed intensive chemotherapy reached CR. Of these, 3 patients are in continious CR for 5+ to 17+ months whereas in I patient meninqeal and bone-marrow relapse occurred after 4 months of CR. From the present albeit limited experience it is concluded that non-endemic Burkitt lymphomas in adults can effectively be treated by combination chemotherapy.
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